$NKTX — one of the cleaner run-up shapes on the board right now. ACR Convergence, Nov 8–9: first-ever autoimmune data for NKX019, Nkarta's off-the-shelf CD19 CAR-NK — myositis oral Sunday, scleroderma poster Monday, plus a safety oral Wednesday. CEO Paul Hastings at Stifel, on the ACR slots: "You don't get an oral presentation at ACR if you have shitty data." He kept coming back to durability + safety — dosed outpatient with just 2 hours of monitoring. The setup: $1.74, sitting on its 52-week low after six months of bleeding, with $3.40 a share in cash on the balance sheet. Market cap ~$125M vs $243M cash, runway into 2029, no raise hanging over the print. You're basically getting the data for free. Safety already telegraphed clean — no CRS, no ICANS in the abstract — so this trades on one thing: real responses in the efficacy cohorts.